Treatment of Sputum Smear-Positive Pulmonary Tuberculosis
For sputum smear-positive pulmonary tuberculosis, initiate a 6-month regimen consisting of an intensive phase of 2 months with four drugs (isoniazid, rifampin, pyrazinamide, and ethambutol) given daily, followed by a 4-month continuation phase with isoniazid and rifampin given daily. 1, 2
Initial Phase (First 2 Months)
Administer all four drugs daily for 56 doses over 8 weeks: 1, 2
- Isoniazid: 5 mg/kg daily (maximum 300 mg) 1, 3
- Rifampin: 10 mg/kg daily (maximum 600 mg) 1, 2
- Pyrazinamide: 15-30 mg/kg daily (for patients <50 kg: 35 mg/kg; for patients >50 kg: 2.0 g daily) 2, 4
- Ethambutol: 15-25 mg/kg daily 2, 4
Ethambutol can be discontinued once drug susceptibility testing confirms full susceptibility to isoniazid and rifampin, typically after 2 months when results return. 1, 2 However, ethambutol should be included initially if the local prevalence of isoniazid resistance exceeds 4%, or if prior drug susceptibility results are unavailable. 1, 3
Continuation Phase (Months 3-6)
Administer isoniazid and rifampin daily for 126 doses over 18 weeks (4 months) in most patients. 1, 2
When to Extend Treatment to 9 Months Total
Extend the continuation phase to 7 months (total 9 months of treatment) in three specific situations: 2
- Cavitary pulmonary tuberculosis on initial chest radiograph AND positive sputum culture at completion of 2 months of treatment 1, 2
- Initial treatment phase did not include pyrazinamide 1, 2
- HIV-positive patients with CD4+ counts <100 cells/mm³ 2
Critical Monitoring Requirements
Bacteriologic Monitoring
- Obtain sputum cultures monthly until two consecutive negative cultures are documented 2, 5
- Patients must demonstrate sputum conversion (culture negativity) within 3 months of treatment initiation 6, 2
- If sputum remains smear-positive at 3 months, immediately reevaluate for nonadherence, treatment failure, or drug resistance 7, 6
Drug Susceptibility Testing
Perform drug susceptibility testing on all initial isolates before starting treatment to confirm susceptibility to at least isoniazid, rifampin, pyrazinamide, and ethambutol. 2, 5 This is essential because 90-95% of patients with drug-susceptible organisms will have negative cultures after 3 months of appropriate multidrug therapy. 6
Directly Observed Therapy (DOT)
All patients with active tuberculosis should receive directly observed therapy, where ingestion of medications is observed by a responsible person. 7, 8 This is the single most important intervention to prevent treatment failure and the development of drug-resistant strains. 7, 3 Clinicians are poor at predicting which patients will adhere to therapy, so DOT should be universal rather than selective. 7
Alternative Dosing Schedules
If daily therapy cannot be implemented, twice-weekly or three-times-weekly regimens may be used, but ONLY with directly observed therapy: 1
- Regimen 2: Daily for 2 weeks, then twice weekly for 6 weeks (initial phase), followed by twice weekly for 16 weeks (continuation phase) 1
- Regimen 3: Three times weekly throughout both phases 1
Doses must be adjusted for intermittent therapy: 1
- Isoniazid: 15 mg/kg (maximum 900 mg) for twice or three-times weekly dosing 3
- Rifampin: doses adjusted accordingly for intermittent schedules 1
Common Pitfalls to Avoid
Never Add a Single Drug to a Failing Regimen
If treatment failure occurs (positive cultures after 4 months of treatment), never add a single drug to the existing regimen—this guarantees acquired resistance to the new drug. 6 Instead, add at least two, and preferably three, new drugs to which the organism is likely susceptible. 6
Do Not Rely on Clinical Improvement Alone
Bacteriologic confirmation of cure is essential; do not stop treatment based solely on clinical or radiographic improvement. 2 Approximately 50% of culture-positive patients will have negative smear results, so negative smears do not exclude active disease. 8
Recognize Treatment Failure Early
Patients whose sputum cultures remain positive after 4 months of treatment should be deemed treatment failures. 6 The most common reasons are nonadherence (most frequent) and drug resistance. 6 Early consultation with a tuberculosis specialist is strongly advised. 6
Monitor for Hepatotoxicity
Baseline and regular monitoring of liver function tests is required in patients with chronic liver disease, alcoholism, chronic active hepatitis, cirrhosis, and hepatitis B or C. 2 In stable liver disease with normal liver enzymes, all first-line drugs may be used, but frequent monitoring is necessary. 2, 4
Special Populations
HIV Co-infection
Use the same standard 6-month regimen for HIV-positive patients, but consider extending treatment to at least 9 months and at least 6 months after documented culture conversion. 2, 5 Screen antimycobacterial drug levels in patients with advanced HIV disease to prevent malabsorption and emergence of resistance. 5, 4
Pregnancy
All first-line drugs (rifampin, isoniazid, ethambutol, pyrazinamide) can be used during pregnancy. 2, 4 Streptomycin is contraindicated due to fetal ototoxicity. 2, 4 Prophylactic pyridoxine 10 mg/day is recommended with isoniazid. 4
Diabetes Mellitus
Use the same standard regimen, but strict control of blood glucose is mandatory. 2, 4 Rifampin reduces the efficacy of sulfonylureas—doses of oral hypoglycemic agents may need to be increased. 2, 4
Pre-existing Liver Disease
In stable liver disease with normal liver enzymes, all anti-tuberculous drugs may be used, but frequent monitoring of liver function tests is required. 2, 4 If pyrazinamide must be omitted due to severe liver disease, use 2 months of isoniazid, rifampin, and ethambutol daily, followed by a 7-month continuation phase (total 9 months). 5
Children
Use rifampin and isoniazid for 6 months, supplemented by pyrazinamide for the first 2 months. 2 Ethambutol should be included in the first 2 months if the same criteria for a fourth drug apply as in adults. 2 Dosing for children: isoniazid 10-15 mg/kg (maximum 300 mg) daily. 3